Prevention and Management of Methicillin-Resistant Staphylococcus aureus (MRSA) Infections
Risk Factors for MRSA Infection
- Prior MRSA infection or colonization is the single strongest risk factor for developing MRSA infection, followed by recent hospitalization, nursing home residence, and recent antibiotic use, especially in patients with chronic comorbidities such as diabetes mellitus 1, 2
- Advanced age, presence of invasive devices, and chronic comorbidities are also risk factors for MRSA infection 2
- Nasal colonization with MRSA occurs in 20-40% of the general population and is a significant risk factor for developing MRSA infection 3, 2
- Post-influenza-like illness is a risk factor for MRSA infection, particularly in patients with severe underlying disease 4, 5
- A Charlson score >5 points increases the risk of S. aureus infections, according to the American College of Physicians 6
- Participation in contact sports, sharing personal items, and certain underlying conditions such as diabetes mellitus, chronic obstructive pulmonary disease (COPD), and immunosuppression increase the risk of S. aureus infections, as reported by the American Academy of Pediatrics, the American Diabetes Association, and the Global Initiative for Chronic Obstructive Lung Disease 6, 7
- High local prevalence of MRSA (>30-50% of S. aureus isolates) is a significant risk factor for developing MRSA infection 2
- Joint prosthetics, dialysis catheters, and hemodialysis increase the risk of S. aureus infections, as stated by the World Health Organization and the National Kidney Foundation 6, 1
| Risk Factor | Description |
|---|---|
| Prior MRSA infection or colonization | Single strongest risk factor for developing MRSA infection |
| Recent hospitalization | Increases risk of MRSA infection |
| Nursing home residence | Increases risk of MRSA infection |
| Recent antibiotic use | Increases risk of MRSA infection |
| Prolonged hospital stay | Increases risk of MRSA infection |
| Invasive devices | Increases risk of MRSA infection |
| Dialysis | Increases risk of MRSA infection |
| Advanced age | Increases risk of MRSA infection |
| Chronic comorbidities | Increases risk of MRSA infection |
| Charlson score >5 points | Increases risk of MRSA infection |
| Social and behavioral risk factors | Close contact with MRSA-colonized individuals, living in crowded conditions, participation in contact sports, injection drug use, men who have sex with men, and children <2 years old |
Prevention and Control Measures
- Empiric MRSA coverage should be considered in patients with a history of previous MRSA infection/colonization within the past year, high local MRSA prevalence, or severe infection, according to the Infectious Diseases Society of America 6, 2
- Active surveillance in high-risk settings, such as intensive care units, is essential for early identification and prevention of MRSA infections 2
- Appropriate hand and skin hygiene, cleaning and disinfecting shared equipment, and prompt treatment of skin wounds are crucial for preventing MRSA infections, as recommended by the Centers for Disease Control and Prevention and the World Health Organization 6, 1
- Applying mupirocin nasal ointment to carriers can reduce recurrences by approximately 50%, and oral clindamycin 150 mg daily for 3 months can reduce subsequent infections by approximately 80% for recurrent furunculosis, as reported by the Infectious Diseases Society of America and the American Academy of Dermatology 3
Treatment of MRSA Infections
- First-line options for MRSA treatment include clindamycin, trimethoprim-sulfamethoxazole, doxycycline, or linezolid, and first-line IV options include vancomycin, linezolid, or daptomycin 8, 9
- The Infectious Diseases Society of America recommends determining vancomycin MIC for all MRSA infections, and considering alternative therapy if no clinical improvement after 3 days with MRSA infection with MIC >1 mg/L 10, 8
- Appropriate antimicrobial stewardship includes de-escalation of therapy based on culture results and clinical response to minimize unnecessary broad-spectrum antibiotic use 10, 8
- Treatment duration for MRSA pneumonia is typically 7-21 days depending on severity, and linezolid does not require therapeutic drug monitoring, unlike vancomycin, which requires trough level monitoring 8, 11